Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial. The company announced Monday that it has ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...

Amgen has said MariTide could offer quicker weight loss, possibly better weight maintenance, and fewer shots than weekly injections such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

--Amgen today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide, an investigational antibody peptide conjugate subcutaneously administered monthly or ...

Amgen released the long-awaited results from its study of weight loss injection MariTide and the results — while promising — are still being evaluated by industry stakeholders. The pharma giant ...

As Amgen (NASDAQ:AMGN) shares are down 9% following the release of highly anticipated phase 2 data on its weight loss drug MariTide, Street analysts are weighing in. And there's a theme: They want ...